Atlas Pulse News

What changed, with source links.

Atlas Pulse monitors peptide research, safety, FDA guidance, and regulatory changes. Open a card for a plain-English read, then use the original source before changing your view.

See What Changed Add updates to Watchlist

Clinical TrialClinicalTrials.govAug 3, 2026

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

A clinical trial found that tirzepatide, a dual GLP-1/GIP agonist peptide, improved functional capacity in patients with reduced ejection fraction heart failure and obesity.

Tirzepatide GLP-1

Related to peptides:

8/10

Read source